Patients, their doctors, nonsteroidal anti-inflammatory drugs and the perception of risk

Arthritis Research and Therapy

Volumn 8, Issue 2, 2006, Pages

  Goldkind, Lawrence ^a   Simon, Lee S ^b  

^a UNIFORMED SERVICES UNIVERSITY OF THE HEALTH SCIENCES   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; CELECOXIB; CYCLOOXYGENASE 2 INHIBITOR; DICLOFENAC; IBUPROFEN; LUMIRACOXIB; NAPROXEN; NON PRESCRIPTION DRUG; NONSTEROID ANTIINFLAMMATORY AGENT; OPIATE; PARACETAMOL; PLACEBO; PROTON PUMP INHIBITOR; ROFECOXIB;

ADENOMATOUS POLYP; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CARDIOTOXICITY; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; DISEASE ASSOCIATION; DISEASE SEVERITY; DOCTOR PATIENT RELATION; DRUG EFFICACY; DRUG MARKETING; DRUG MEGADOSE; DRUG POTENTIATION; DRUG SAFETY; EXERCISE; GASTROINTESTINAL HEMORRHAGE; GASTROINTESTINAL TOXICITY; HEART INFARCTION; HIGH RISK PATIENT; HUMAN; HYPERTENSION; INTERNET; LOW DRUG DOSE; MEDICAL DECISION MAKING; NONHUMAN; OSTEOARTHRITIS; PEPTIC ULCER; POSTMARKETING SURVEILLANCE; POSTOPERATIVE PAIN; QUANTITATIVE ANALYSIS; RHEUMATOID ARTHRITIS; RISK ASSESSMENT; RISK BENEFIT ANALYSIS; RISK REDUCTION; STROKE; SUDDEN DEATH; PATIENT; PHYSICIAN;

ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; HUMANS; PATIENTS; PHYSICIANS; RISK ASSESSMENT;

EID: 33645724334     PISSN: 14786354     EISSN: None     Source Type: Journal    
DOI: 10.1186/ar1924     Document Type: Article

References (15)

1. Food and Drug Administration Arthritis Advisory Committee [http://www.fda.gov/ohrms/dockets/ac/03/briefing/3930b2.htm]
2. When is a medical product too risky? An interview with FDA's top drug official [http://www.fda.gov/fdac/features/1999/599_med.html]
3. Silverstein FE, Faich G, Goldstein JL, Simon LS, Pincus T, Whelton A.Makuch R, Eisen G, Agrawal NM, Stenson WF: Gas-trointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: a randomized controlled trial. JAMA 2000, 284:1247-1255.
4. Bombardier C, Laine L, Reicin A, Shapiro D, Burgos-Vargas R, Davis B, Day R, Ferraz MB, Hawkey CJ, Hochberg MC: Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group. N Engl J Med 2000, 343:1520-1528.
5. Javonovic BD, Levy PS: A look at the rule of three. Am Statistician 1997, 51:137-139.
6. US Food and Drug Administration FDA and Industry to Collaborate on Better Ways to Predict Liver Toxicity in Human Drug Trials [http://www.fda.gov/bbs/topics/NEWS/2005/NEW01253.html]
7. Draft Guidance of Industry: Good Pharmacovigilance Practices and Pharmacoepidemiologic Assessment 2004 [http://www.fda.gov/cder/guidances/ 5767dft.doc]
8. MedWatch website [http://www.fda.gov/medwatch/]
9. Szarfman A, Machado SG, O'Neill RT: Use of screening algorithms and computer systems to efficiently signal higher than expected combinations of drugs and events in the US FDA's spontaneous reports database. Drug Safety 2002, 25:381-392.
10. DuMouchel W: A Bayesian datamining in large frequency tables, with an application to the FDA spontaneous reporting system. Am Statistician 1999, 53:190-196.
11. Celebrex Approved Labeling [http://www.accessdata.fda.gov/scripts/cder/ onctools/summary.cfm?ID=237]
12. Singh G: Gastrointestinal complications of prescription and over the counter nonsteroidal anti-inflammatory drugs: a view from the Aramis Database. Am J Ther 2000, 7:115-121
13. Farkouh ME, Kirshner H, Harrington RA, Ruland S, Vereught FW, Schnitzer TJ, Burmester GR, Mysler E, Hochberg MC, Doherty M, et al., TARGET Study Group: Comparison of lumiracoxib with naproxen and ibuprofen in the Therapeutic Arthritis Research and Gastrointestinal Event Trial (TARGET), cardiovascular outcomes: randomised controlled trial. Lancet 2004, 364:675-684.
14. FDA Drug Safety and Risk Management Advisory Committee: Food and Drug Administration Notice [http://www.fda.gov/OHRMS/DOCKETS/98fr/05-958.htm]
15. Simon LS, Strand V: The pharmacologic therapy of OA. In Osteoarthritis. Edited by Moskowitz RM, Howell D, Altman RA, Buckwalter JA, Goldberg VM. Philadelphia, PA: Saunders; 2001.